Bruker Story

<div class='circular--portrait' style='background:#FF0F00;color: #FFFFF0;font-size:4em;'>BC</div>
BRKR -- USA Stock  

USD 62.21  0.11  0.18%

While many traders are getting carried away by overanalyzing healthcare space, it is reasonable to sum up Bruker. We will analyze why Bruker investors may still consider a stake in the business. Is the entity valuation justified? I am going to cover the stock perspective on valuation to give you a better outlook on taking a position in it.
Published over a week ago
View all stories for Bruker Corp | View All Stories
Is Bruker (NASDAQ:BRKR) ready for a correction?
Bruker currently holds 910.2 M in liabilities with Debt to Equity (D/E) ratio of 0.95, which is about average as compared to similar companies. This firm has a current ratio of 2.62, suggesting that it is liquid enough and is able to pay its financial obligations when due. Macroaxis provides unbiased investment recommendation on Bruker that should be used to complement current analysts and expert consensus on Bruker. Our trade advice engine determines the company's potential to grow exclusively from the perspective of an investors' current risk tolerance and investing horizon.
We determine the current worth of Bruker Corp using both absolute as well as relative valuation methodologies to arrive at its intrinsic value. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Bruker Corp based exclusively on its fundamental and basic technical indicators. By analyzing Bruker Corp's financials, quarterly and monthly indicators, and related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Bruker Corp's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Bruker Corp. We calculate exposure to Bruker Corp's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Bruker Corp's related companies.

Bruker Corp Investment Alerts

Bruker investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring Bruker Corp performance across your portfolios.Please check all investment alerts for Bruker

Bruker Corp Valuation Ratios as Compared to Competition

Our valuation model uses many indicators to compare Bruker value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Bruker Corp competition to find correlations between indicators driving the intrinsic value of Bruker.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions.
It is good to see analyst projects for Bruker Corp, but it might be worth checking our own buy vs. sell analysis

What is driving Bruker Corp Investor Appetite?

The company reported the previous year's revenue of 1.96 B. Net Income was 157.5 M with profit before overhead, payroll, taxes, and interest of 1000 M.

Margins Breakdown

Bruker profit margins show the degree to which it makes money. Margin indicators are used not only by investors but also by creditors or Bruker itself as indicators of financial health and management effectiveness. Please look more closely at the different varieties of Bruker profit margins.
Operating Margin11.28
EBITDA Margin0.18
Gross Margin0.56
Profit Margin0.0949


Bruker Earnings Before Interest Taxes and Depreciation Amortization EBITDA is increasing over the last 8 years. The previous year's value of Bruker Earnings Before Interest Taxes and Depreciation Amortization EBITDA was 345,426,316. Bruker Average Assets is increasing over the last 8 years. Additionally, Bruker Earnings Before Interest Taxes and Depreciation Amortization USD is increasing over the last 8 years. The latest value of Bruker Earnings Before Interest Taxes and Depreciation Amortization USD is 345,426,316. Bruker Earnings Before Interest Taxes and Depreciation Amortization EBITDA is increasing over the last 8 years. The previous year's value of Bruker Earnings Before Interest Taxes and Depreciation Amortization EBITDA was 345,426,316. Bruker Average Assets is increasing over the last 8 years. Additionally, Bruker Earnings Before Interest Taxes and Depreciation Amortization USD is increasing over the last 8 years.

Will Bruker growth be trustworthy after the spike?

Downside deviation is down to 1.59. It may connote a possible volatility fall. Bruker has relatively low volatility with skewness of -0.06 and kurtosis of -0.52. However, we advise all investors to independently investigate Bruker to ensure all accessible information is consistent with the expectations about its upside potential and future expected returns.

Our Final Takeaway

While other companies under the medical devices industry are still a bit expensive, Bruker may offer a potential longer-term growth to retail investors. To conclude, as of the 16th of February 2021, we believe Bruker is currently overvalued. It barely shadows the market and projects very low probability of bankruptcy in the next two years. However, our final 30 days buy-hold-sell recommendation on the enterprise is Strong Buy.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Bruker Corp. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com